Letters to the Editor

Letters to the Editor are no longer included in the main BJUI journal, but we will continue to publish them on the BJUI website as an important part of the scientific debate.

Letters Policy

  • Letters to the editor will now published in electronic form on the journal website (www.bjuinternational.com), not in the journal itself. As such, letters are not submitted to PubMed for indexing.
  • Letters to the editor should be 500 words or less, preference is given to concise letters.
  • Writers are limited to one letter published on the website per month.
  • Letters must include full author contact details.
  • All letters will be peer-reviewed, and we reserve the right to reject letters, or to edit them if they are accepted.
  • If accepted, letters are sent to the authors of the paper being discussed, to give them the chance to make a response that will (if accepted) be published at the same time as the letter.
  • Letters will not be open for public comment; replies must be submitted by email to the Editorial Office for review.

RE: Outcomes of high complex renal tumor (PADUA ≥ 10) following robot-assisted partial nephrectomy with a median 46 months follow-up: A tertiary center experience

Letter to the Editor Outcomes of high complex renal tumor (PADUA ≥ 10) following robot-assisted partial nephrectomy with a median 46 months follow-up: A tertiary center experience Sir, We read this article by Raheem et al with great interest and appreciate the efforts of the authors to publish the largest single centre data on outcomes of high complexity tumors with PADUA score>10 [1]. We wish to highlight a few points. In table 1 the T stage classification has been applied to all the…

RE: Opportunity of widening the resort to multiparametric MRI/transrectal ultrasound fusion imaging-guided prostate cancer brachytherapy

Sir, Thank you for your interest in our article regarding whole-gland brachytherapy to the prostate for prostate cancer (1). Your letter is highlighting the expanding role of brachytherapy to that of focal therapy (2). We agree that multiparametric magnetic resonance imaging (mpMRI) scans have expanded the ability to localise tumours and indeed that they may be useful in carefully selected men wishing to undergo focal therapy. However, other  advances such as the use of fiducial markers and spacers…

RE: Prostate Carcinoma With Positive Margins at Radical Prostatectomy: Role of Tumour Zonal Origin in Biochemical Recurrence

Sir, With great interest, we read the recent article by O’Neil et al. [1], in which the authors investigated the relation between the tumour zonal origin (transition zone vs peripheral zone), positive surgical margins (PSM) after radical prostatectomy and the risk of biochemical recurrence (BCR). Clinicopathological data for 323 patients with PSM after prostatectomy were analysed, of which tumours arising in the prostate transition zone (TZ) were 13%, while tumours in the peripheral zone (PZ)…

RE: In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?

Sir, We read with much interest the work of Salami [1], which strengthens the evidence in favour of a mpMRI targeted biopsy (TBx) in the diagnostic work-up of patients with persistent clinical suspicion of prostate cancer (PCa). TBx can indeed improve the detection rate of prostate biopsy  without the need of a systematic sampling, especially in presence of previous negative histological findings [2]. TBx might also reduce the risk of biopsy-related complications, as much as improve patient quality…

Cumulative cancer length in selecting candidates for Active Surveillance: use or abuse?

Sir, Chen et al. [1] have performed an interesting evaluation on  cumulative cancer length on prostate needle biopsy (Bx) divided by the number of biopsy cores (CCL/core) in predicting outcomes after radical prostatectomy (RP) in candidates for Active Surveillance (AS). Criticisms against AS criteria could concern the relevant proportion of upstaging, upgrading or unfavourable cancer in subjects with apparently low- or favourable-risk PCa [2]. To this regard, AS has gained popularity with…
© 2024 BJU International. All Rights Reserved.